Mon, June 22, 2026
AUS Edition NZ Edition UK Edition
CA Edition USA Edition IND Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. ESPR
Healthcare
Facebook Twitter Linkedin

Esperion Therapeutics Inc (NASDAQ:ESPR)

3.15 USD

-0.020 0.631%
Last Updated at: 2026-06-18T23:51:00Z

Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

3891 Ranchero Drive, Ann Arbor, MI, United States, 48108

734 887 3903

https://www.esperion.com

Employees: 294

Key Executives

Sr. No. Name Title Year Born
1. Mr. Sheldon L. Koenig Pres, CEO & Director 1966
2. Dr. JoAnne Micale Foody FACC, M.D. Chief Medical Officer 1965
3. Mr. Benjamin Halladay M.B.A. Chief Financial Officer NA
4. Mr. Kenneth J. Fiorelli Chief Technical Operations Officer NA
5. Mr. Benjamin O. Looker Gen. Counsel 1982
6. Ms. Betty Jean Swartz Chief Strategy Officer NA
7. Mr. Eric J. Warren R.Ph. Chief Commercial Officer 1972
8. Mr. Sheldon L. Koenig President, CEO & Director 1966
9. Mr. Benjamin O. Looker General Counsel 1982
10. Dr. JoAnne Micale Foody FACC, M.D. Chief Medical Officer 1966

Peers

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
ZTS

Zoetis Inc

 +1.450 1.877% 77.73 40.180 30.960 10.675 17.597 11.271 26.180
MKKGY

Merck KGaA ADR

 0.000 0.000% 30.45 21.250 14.925 3.099 2.143 3.605 12.978
MKGAF

MERCK Kommanditgesellschaft auf Aktien

 0.000 0.000% 157.12 21.730 14.948 3.159 2.147 3.562 12.822
GALDY

GALDERMA GROUP AG

 -0.330 0.763% 43.55 74.210 41.667 8.636 5.553 9.151 42.220

Income Statement

(Currency in USD)
Breakdown 31-12-2025 31-12-2024 31-12-2023 31-12-2022 31-12-2021
Income Before Tax -20.841M -51.745M -209.248M -233.659M -269.108M
Minority Interest - - - - -
Net Income -22.682M -51.745M -209.248M -287.817M -318.824M
Selling General Administrative 165.786M 137.573M 126.923M 136.049M 199.202M
Gross Profit 273.911M 263.713M 73.067M 48.508M 64.23M
Reconciled Depreciation 0.105M 0.063M 0.25M 0.5M 0.612M
Ebit 60.168M 7.506M -150.272M -179.501M -226.73M
Ebitda 60.273M 7.569M -150.108M -176.849M -222.755M
Depreciation And Amortization 0.105M 0.063M 0.164M 2.652M 3.975M
Operating Income 60.273M 54.402M -155.563M -179.501M -226.73M
Other Operating Expenses 342.862M 277.912M 271.897M 254.976M 305.177M
Interest Expense 84.604M 59.251M 58.976M 56.81M 46.353M
Tax Provision 1.841M 0M 0M - -
Interest Income - - - - -
Net Interest Income -84.604M -59.251M -58.248M -56.81M -46.353M
Income Tax Expense 1.841M -51.745M -0.004M 54.158M 49.716M
Total Revenue 403.135M 332.314M 116.334M 75.475M 78.447M
Total Operating Expenses 213.638M 209.311M 228.63M 228.009M 290.96M
Cost Of Revenue 129.224M 68.601M 43.267M 26.967M 14.217M
Total Other Income Expense Net -81.114M -106.147M -53.685M -54.158M -42.378M
Net Income From Continuing Ops -22.682M -51.745M -208.391M -233.659M -269.108M
Net Income Applicable To Common Shares - - - -233.659M -269.108M

Balance Sheet

(Currency in USD)
Breakdown 31-12-2025 31-12-2024 31-12-2023 31-12-2022 31-12-2021
Total Assets 465.886M 343.821M 205.796M 247.939M 381.59M
Intangible Assets 0.056M 0.056M 0.056M 0.056M 0.056M
Other Current Assets -245.314M 18.604M 4.7M 9.866M 62.752M
Total Liab 767.851M 732.543M 660.79M 571.717M 578.534M
Total Stockholder Equity -301.965M -388.722M -454.994M -1340.036M -1106.377M
Other Current Liab 146.044M 81.163M 62.723M 65.377M 48.718M
Common Stock 0.245M 0.196M 0.118M 0.075M 0.061M
Capital Stock 0.245M 0.196M 0.118M 0.075M 0.061M
Retained Earnings -1623.711M -1601.029M -1549.284M -1340.036M -1106.377M
Good Will - - - - -
Other Assets - - 0M - 50M
Cash 167.852M 144.761M 82.248M 124.775M 208.892M
Cash And Equivalents - - - - -
Total Current Liabilities 300.81M 246.233M 156.224M 92.308M 73.352M
Current Deferred Revenue - 8.518M 25.402M 3.507M 5.683M
Net Debt 380.148M 446.451M 458.699M 136.173M 51.304M
Short Term Debt 89.698M 104.902M 36.381M 0.384M 1.392M
Short Long Term Debt - 54.575M - - -
Short Long Term Debt Total 548M 591.212M 540.947M 260.948M 260.196M
Other Stockholder Equity 1321.501M 1212.111M 1094.172M -0.073M -0.03M
Property Plant Equipment - - - 0.164M 0.664M
Total Current Assets 167.852M 337.998M 201.065M 246.683M 328.972M
Long Term Investments - - - 42.086M 50.441M
Short Term Investments - - 0M 42.086M 50.441M
Net Receivables 140.19M 80.142M 48.494M 33.729M 22.934M
Long Term Debt 249.479M 237.716M 261.596M 259.899M 258.28M
Inventory 105.124M 94.491M 65.623M 35.201M 34.394M
Accounts Payable 65.068M 51.65M 31.718M 23.04M 17.559M
Accumulated Other Comprehensive Income - - 0M -0.002M -0.031M
Non Currrent Assets Other -123.133M - -0M -42.086M 50M
Non Current Assets Total 298.034M 5.823M 4.731M 1.256M 52.618M
Capital Lease Obligations 2.755M 5.311M 4.573M 1.049M 1.916M
Long Term Debt Total - - - - -

Cash Flow

(Currency in USD)
Breakdown 31-12-2025 31-12-2024 31-12-2023 31-12-2022 31-12-2021
Investments 0M -0.317M 30.706M 8.104M -50.484M
Total Cashflows From Investing Activities 0.189M -0.317M 42.5M 8.104M -50.484M
Total Cash From Financing Activities 36.184M 86.484M 50.46M 32.606M 268.223M
Net Income -22.682M -51.745M -209.248M -233.659M -269.108M
Change In Cash 23.091M 62.513M -42.527M -134.117M -46.07M
Begin Period Cash Flow 144.761M 82.248M 124.775M 258.892M 304.962M
End Period Cash Flow 167.852M 144.761M 82.248M 124.775M 258.892M
Total Cash From Operating Activities -13.093M -23.654M -135.487M -174.827M -263.809M
Depreciation 0.105M 0.063M 0.164M 0.5M 0.612M
Other Cashflows From Investing Activities - - - - -
Dividends Paid 0M 0M 0M 0M 0M
Change To Inventory -10.633M -28.868M -30.422M -0.807M -18.258M
Sale Purchase Of Stock - - - 90.849M 222.45M
Other Cashflows From Financing Activities 0.244M -39.715M -6.416M -58.243M 50.29M
Capital Expenditures 0.189M 0.317M 0M 0M 0M
Change In Working Capital -14.642M -60.53M 13.675M -3.373M -52.513M
Other Non Cash Items 14.256M 76.565M 47.964M 46.49M 35.528M
Free Cash Flow -12.904M -23.971M -135.487M -174.827M -263.809M

Funds

Sr. No. Name Purchased On Shares
1. Vanguard Total Stock Mkt Idx Inv 2 months ago 7525646
2. iShares Russell 2000 ETF 2 months ago 5847555
3. Wasatch Ultra Growth 5 months ago 4415356
4. Pender Corporate Bond A 5 months ago 4058688
5. Nuveen Quant Small Cap Equity R6 3 months ago 3016380
6. Biotech Growth Ord 5 months ago 2941498
7. Wasatch Micro Cap 5 months ago 2817014
8. Vanguard Institutional Extnd Mkt Idx Tr 2 months ago 2665819
9. Fidelity Small Cap Index 4 months ago 2266600
10. State Street® SPDR® S&P® PhrmctlsETF 2 months ago 2194800
11. Russell 2000 Equity Index Fund B 5 months ago 1464808
12. State St Russell Sm/Mid Cp® Indx SL Cl I 2 months ago 1364342
13. iShares Russell 2000 Value ETF 2 months ago 1357675
14. Fidelity Extended Market Index 3 months ago 1249357
15. Vanguard Russell 2000 ETF 2 months ago 1185809
16. Royce Micro-Cap Trust 2 months ago 1124331
17. Xtrackers MSCI World Swap ETF 1C 5 months ago 904852
18. Vanguard Explorer Inv 5 months ago 829785
19. Royce Small-Cap Composite 5 months ago 795830
20. State St Russell Sm Cap® Indx SL Cl I 3 months ago 775900

Institutions

Sr. No. Name Purchased On Shares
1. Vanguard Group Inc 5 months ago 14945454
2. BlackRock Inc 8 months ago 14833791
3. Two Seas Capital LP 5 months ago 11902521
4. Wasatch Advisors LP 5 months ago 9445759
5. D. E. Shaw & Co LP 5 months ago 6903483
6. Orbimed Advisors, LLC 5 months ago 5965498
7. Geode Capital Management, LLC 5 months ago 5737651
8. Marshall Wace Asset Management Ltd 5 months ago 5471611
9. Two Sigma Investments LLC 5 months ago 4742082
10. State Street Corp 8 months ago 4478834
11. Penderfund Capital Management Ltd 5 months ago 4391926
12. Morgan Stanley - Brokerage Accounts 8 months ago 4055626
13. AIGH Capital Management, LLC 5 months ago 4000000
14. Millennium Management LLC 5 months ago 3932274
15. Eversept Partners, LP 5 months ago 3851133
16. Nuveen, LLC 5 months ago 3612113
17. Royce & Associates, LP 5 months ago 3601523
18. Two Sigma Advisers, LLC 5 months ago 3505200
19. The Goldman Sachs Group Inc 5 months ago 2848216
20. Renaissance Technologies Corp 5 months ago 2194600
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Sponsored Articles

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App